Unique ID issued by UMIN | UMIN000011693 |
---|---|
Receipt number | R000013672 |
Scientific Title | Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer |
Date of disclosure of the study information | 2013/09/09 |
Last modified on | 2013/09/09 23:49:28 |
Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer
Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate
Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate in patients with unresectable advanced or recurrent breast cancer
Pharmacokinetics, pharmacodynamics and pharmacogenetics study of eribulin mesylate
Japan |
Unresectable advanced or recurrent breast cancer
Hematology and clinical oncology |
Malignancy
YES
By the blood drug concentration measurement, we will reveal the characteristics of the pharmacokinetics / pharmacodynamics of plasma eribulin in patients with elderly, ECOG performance status failure, or organ dysfunction patients, especially.
Furthermore, we will perform a correlated analysis of eribulin toxicity and pharmacokinetic / pharmacodynamic.
In addition, we consider the predictive factors of high-risk patients who require postponement of eribulin administration, discontinuation, or dose reduction. As one of the predictive factor, we consider the pharmacokinetics control factors such as eribulin transporter. We will analyze the gene polymorphism of transporters, and carry out correlation analysis of adverse events and pharmacogenetic features.
PK,PD
Not applicable
-Pharmacokinetic analysis of eribulin
-Correlation between effectiveness/toxicity and pharmacokinetics of eribulin
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Eribulin mesylate administer day 1, day 8, tri-weekly interval. The trial treatment will be continued until there is progressive disease. we will evaluate the variation of eribulin pharmacokinetics at cycle1 day1.
20 | years-old | <= |
75 | years-old | > |
Female
a)Histological confirmation of invasive breast cancer
b)Unresectable locally advanced cases (T4 case) or recurrent breast cancer
c)It does not matter dosing history of anthracycline, taxane, vinca alkaloid agents, 5-FU-based anti-cancer agent (UFT, capecitabine, S-1).
d)Patients with no treated with eribulin.
e)Patients wit 75 years of age 20 years of age or older obtaining informed consent
f)PS (ECOG) 0 to 2
g)Patients with passed for more than 2 weeks from prior treatment (chemotherapy, radiation therapy, hormon therapy).
h)Patients with the following values in their latest laboratory tests
-Neutrophil count > 1,000/mm3
-Platelet count > 75,000/mm3
-Hemoglobin > 9.0/dL
-Serum AST/ALT < 5 x Upper Normal Limits
-Serum creatinine < 1.5 mg/dL
a)Patients with brain metastases with symptoms
b)Patients with the body cavity fluid marked (pleural effusion, ascites, pericardial effusion). However, it can be registered if good control due to the administration of adhesion agent.
c)Patients with synchronous double cancer, not including lesions equivalent to carcinoma in situ or mucosal carcinoma considered healed with topical therapy
d)Patients with complications is determined causing serious problems in the implementation of treatment
- Patients with poor control diabetes
- Patients with activity infection
- Patients with pulmonary fibrosis or interstitial pneumonia on chest X-ray
- Patient with protocol difficult-to-treat caused by the mental state or neuropsychiatric disorders
- Patients with watery diarrhea chronic
- Patients with ileus, significant bleeding tendency, and gastrointestinal bleeding
- Patients with uncontrolled angina and myocardial infarction and heart disease merger severe cases with heart failure that developed within three months
e)Pregnant or breast-feeding women, or women of child bearing potential who intend to become pregnant
50
1st name | |
Middle name | |
Last name | Kenji Tamura |
National Cancer Center Hospital
Breast and Medical Oncology Division
5-1-1 Tsukiji, Chuo-ku, Tokyo104-0045, Japan
03-3542-2511
ketamura@ncc.go.jp
1st name | |
Middle name | |
Last name | Kenji Tamura |
National Cancer Center Hospital
Breast and Medical Oncology Division
5-1-1 Tsukiji, Chuo-ku, Tokyo104-0045, Japan
03-3542-2511
ketamura@ncc.go.jp
National Cancer Center Hospital
Japan Medical Association
Non profit foundation
NO
2013 | Year | 09 | Month | 09 | Day |
Unpublished
Enrolling by invitation
2013 | Year | 08 | Month | 28 | Day |
2013 | Year | 09 | Month | 05 | Day |
2013 | Year | 09 | Month | 09 | Day |
2013 | Year | 09 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013672
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |